QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.106.104737v1 318/3/1083    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ilyin, V. I. Articles by Woodward, R. M. Search for Related Content PubMed PubMed Citation Articles by Ilyin, V. I. Articles by Woodward, R. M.

NEUROPHARMACOLOGY

Pharmacology of 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: A Potent, Broad-Spectrum State-Dependent Sodium Channel Blocker for Treating Pain States

Discovery Research, Purdue Pharma LP, Cranbury, New Jersey (V.I.I., P.I.T., S.O.); Algos Therapeutics, St. Paul, Minnesota (J.D.P., S.G.); Wyeth Research, Princeton, New Jersey (G.T.W., J.E.H.); Merck and Company, West Point, Pennsylvania (M.S.P.); Schering Plough Research Institute, Kenilworth, New Jersey (L.M.); Novartis Pharmaceutical Corporation, East Hanover, New Jersey (R.B.C.); Allergan, Inc., Irvine, California (P.N.); Department of Pharmacology, University of California, Irvine, California (D.J.H.); Amicus Therapeutics, Cranbury, New Jersey (E.B.); and Adolor Corporation, Exton, Pennsylvania (R.M.W.)

Voltage-gated Na⁺ channels may play important roles in establishing pathological neuronal hyperexcitability associated with chronic pain in humans. Na⁺ channel blockers, such as carbamazepine (CBZ) and lamotrigine (LTG), are efficacious in treating neuropathic pain; however, their therapeutic utility is compromised by central nervous system side effects. We reasoned that it may be possible to gain superior control over pain states and, in particular, a better therapeutic index, by designing broad-spectrum Na⁺ channel blockers with higher potency, faster onset kinetics, and greater levels of state dependence than existing drugs. 2-[4-(4-Chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide (PPPA) is a novel structural analog of the state-dependent Na⁺ channel blocker V102862 [4-(4-fluorophenoxy)benzaldehyde semicarbazone]. Tested on recombinant rat Na_v1.2 channels and native Na⁺ currents in cultured rat dorsal root ganglion neurons, PPPA was approximately 1000 times more potent, had 2000-fold faster binding kinetics, and 10-fold higher levels of state dependence than CBZ and LTG. Tested in rat pain models against mechanical endpoints, PPPA had minimal effective doses of 1 to 3 mg/kg p.o. in partial sciatic nerve ligation, Freund's complete adjuvant, and postincisional pain. In all cases, efficacy was similar to clinically relevant comparators. Importantly, PPPA did not produce motor deficits in the accelerating Rotarod assay of ataxia at doses up to 30 mg/kg p.o., indicating a therapeutic index >10, which was superior to CBZ and LTG. Our experiments suggest that high-potency, broad-spectrum, state-dependent Na⁺ channel blockers will have clinical utility for treating neuropathic, inflammatory, and postsurgical pain. Optimizing the biophysical parameters of broad-spectrum voltage-gated Na⁺ channel blockers may lead to improved pain therapeutics.

Address correspondence to: Victor I. Ilyin, Discovery Research, Purdue Pharma LP, 6 Cedar Brook Drive, Cranbury, NJ 08512. E-mail: victor.ilyin{at}pharma.com